Auris Medical Holding (EARS) Reports Q3 Loss of $0.14

Auris Medical Holding (NASDAQ: EARS) reported Q3 EPS of ($0.14), versus ($1.36) reported last year.

"We have continued to make great progress with our intranasal betahistine program and recently reached a major milestone as the second Phase 1 clinical trial showed exciting results", stated Thomas Meyer, Auris Medical's founder, Chairman and CEO. "These positive outcomes include the confirmation of superior bioavailability provided by the intranasal delivery route over the currently used oral administration route, which is the cornerstone of the program. In addition, the trial confirmed that intranasal betahistine is safe and well tolerated even when taken in multiple doses. We look forward to taking our next key development steps with this program that is the start of our planned proof-of-concept studies in acute vertigo and olanzapine-induced weight gain."

For earnings history and earnings-related data on Auris Medical Holding (EARS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c